Latest news and press releases about Adlai Nortye Ltd. (ANL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.
Price
| Price | $15.52 |
| Market Cap | $824M |
| Exchange | NASDAQ |
| Country | SG |
Valuation Ratios
| Price / Book | 1.17 |
| EV / EBITDA | -32.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -21.82% |
| Return on Invested Capital | -9.23% |
| Return on Assets | -9.07% |
| Gross Margin | 100.00% |
| Operating Margin | -113.28% |
| Net Margin | -114.48% |
Related companies: ADAP · ADTX · AIMD · APLM · BLRX · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of ANL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks